21:35 , Apr 17, 2019 |  BC Extra  |  Preclinical News

Atomwise unveils Chagas disease compounds from AIMS program

Atomwise has revealed the first hit identifications by two of its AIMS program collaborators, including compounds against an unexploited target for Chagas disease, for which there are few therapies. On Tuesday, Atomwise Inc. (San Francisco,...
07:00 , May 15, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Chagas disease Cruzain An SAR study identified a small molecule irreversible inhibitor of cruzain that may be useful for treating...
07:00 , Jul 7, 1997 |  BC Week In Review  |  Company News

ArQule, University of California deal

The parties will collaborate on the discovery and design of protease inhibitors, initially targeting Kaposi's sarcoma, herpes virus, a Chagas disease protease called cruzain , and HIV. ARQL will assess and select compounds from its...